News Longeveron Inc.

Equities

LGVN

US54303L2034

Real-time Estimate Cboe BZX Other stock markets 08:34:02 01/05/2024 pm IST			5-day change	1st Jan Change
1.745 ^USD	+2.05%		+1.16%	-87.21%

30/04	Longeveron Files Prospectus for Secondary Offering	MT
15/04	Top Premarket Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Longeveron Files Prospectus for Secondary Offering	30/04	MT
Longeveron to Present at the Planet MicroCap Showcase	26/04	AQ
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering	19/04	AQ
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds	17/04	AQ
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation	16/04	AQ
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)	15/04	AQ
Top Premarket Gainers	15/04	MT
Longeveron Announces Closing of $5.2 Million Public Offering	12/04	AQ
Longeveron Announces Pricing of $5.25 Million Public Offering	08/04	AQ
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals	08/04	AQ
Top Premarket Gainers	08/04	MT
Longeveron to Effect 1-for-10 Reverse Stock Split	20/03	MT
Longeveron Announces 1-for-10 Reverse Stock Split	20/03	AQ
Transcript : Longeveron Inc., 2023 Earnings Call, Feb 27, 2024	28/02
Longeveron Reports Year-End 2023 Results and Provides Corporate Update	28/02	AQ
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024	22/02	AQ
Transcript : Longeveron Inc. - Shareholder/Analyst Call	21/02
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™	29/01	AQ
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind Its Lead Investigation Product Lomecel-B	29/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Longeveron Inc.

Equities

LGVN

US54303L2034

Summary

Filters